Manufactures and simulates living human tissue so drug developers can test toxicity and response before clinical trials
Polyphron is a New York company building 'artificial human biology': it manufactures donor-defined living human tissue in an automated foundry, perturbs it in controlled ways, tracks how it changes over time, and trains world models of tissue behavior so biotech, pharma and AI labs can test whether a drug will cause, for example, cardiac or liver toxicity before it reaches patients. Cardiac tissue is in production and liver is next. It was co-founded by CEO Matthew Osman and CSO Fabio Boniolo, with Chief AI Scientist Vinh Q. Tran (ex-Google DeepMind) joining as a co-founder in September 2026, and announced a $20M seed led by Quiet Capital with Gradient, Haystack and Compound on September 17, 2026.
Biotech📍 New York, NY
Current Valuation
Private
PRIVATE
IPO Outlookprivate
Is Polyphron going public?
No. Polyphron is private and has not filed to go public. There is no S-1 on file.
What is Polyphron's valuation in 2026?
No confirmed valuation is on record for Polyphron. The roster shows funding and investors where they are public; it does not estimate a mark.
Has Polyphron filed an S-1?
No public S-1 is on file for Polyphron.
Who are Polyphron's investors?
Polyphron's investors include Quiet Capital, Gradient, Haystack, Compound.
How much has Polyphron raised?
Polyphron has raised $20M in total across 1 disclosed round, most recently a Seed of $20M in Sep 2026.
Is Polyphron publicly traded — can you buy Polyphron stock?
No. Polyphron is a private company — its shares are not listed on any exchange and there is no ticker. The routes to exposure are pre-IPO secondary marketplaces and funds (accredited investors), employee tender offers when the company runs one, and public companies with read-through exposure. QuantLogix maps every route it can verify for Polyphron on its Pre-IPO Access Desk.
Answers are derived from the roster record shown on this page — filing status, last round and confirmed marks. Where the record is silent, the answer says so rather than guessing.
Company Profile
CEO
Matthew Osman
HQ
New York, NY
Total Raised
$20M
Growth
Cardiac tissue in production, liver next; plans tissue from 20+ donors
Last Round
Seed — $20M (Sep 2026) · Lead: Quiet Capital
IPO Status
private
Fundraising Status
Seed · $20M · 1 mo ago
privateTotal raised $20M1 disclosed rounds
Funding History
Round
Amount
Date
Lead Investor
Post-Money
Seed
$20M
Sep 2026
Quiet Capital
—
Vertical Intelligence — Biotech / Gene Therapy
Biotech / Gene Therapy registry data for Polyphron has not been collected yet — the weekly vertical sweep hasn't reached this company. Check back soon.
Talent Signal
Hiring data for Polyphron has not been collected yet — the monthly talent sweep hasn't reached this company. Check back soon.
Founders & Key People
Matthew OsmanFabio BonioloVinh Q. Tran
Investors
Quiet Capital · Gradient · Haystack · Compound
Products
Automated tissue foundry producing donor-defined human tissues (cardiac in production across multiple donor lines; liver next for drug metabolism and liver toxicity)
Tissue world models trained on longitudinal data from perturbed living tissue to predict toxicity and response
Studies testing customers' drug candidates on living human tissue, plus datasets and benchmarks for biological AI models
BiotechAI Drug DiscoveryTissue EngineeringToxicologyRecently Funded
Private-company numbers are not real-time. Reflects publicly disclosed valuations from press releases, news reports, and tender offers as of recent date. Refreshed quarterly.